IPO registrations (S-1, F-1) · Registrants
GENETIC TECHNOLOGIES LTD
- SEC CIK
- 1166272 · filings on EDGAR ↗
- Former names
- GENETIC TECHNOLOGIES LTD /FI (2001–2002)
- Registration
- Form F-1, first filed 2019-12-17, last 2024-05-20; 2 initial registrations, 2 amendments
- Outcome
- Final prospectus filed 2020-05-28; declared effective 2020-03-23
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Business address
- SUITE 7, LEVEL 1, 321 CHAPEL STREET, Prahran Victoria, C3 3181
- EDGAR entity type
- other
Offering terms
- Final price
- $2.00 per ADS (424B4 filed 2020-05-28)
- Shares sold
- 500,000
- Gross proceeds
- $1,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol GENE
- Lead underwriters
- Wainwright & Co
- Syndicate
- H.C. Wainwright
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
Filings 9
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2019-12-17 | F-1 | F-1 (foreign registration) | GENETIC TECHNOLOGIES LTD | 0001104659-19-073211 ↗ |
| 2019-12-18 | F-1/A | F-1/A (amendment) | GENETIC TECHNOLOGIES LTD | 0001104659-19-073882 ↗ |
| 2020-03-23 | EFFECT | EFFECT (declared effective) | GENETIC TECHNOLOGIES LTD | 9999999995-20-000611 ↗ |
| 2020-05-12 | F-1/A | F-1/A (amendment) | GENETIC TECHNOLOGIES LTD | 0001493152-20-008348 ↗ |
| 2020-05-26 | EFFECT | EFFECT (declared effective) | GENETIC TECHNOLOGIES LTD | 9999999995-20-001246 ↗ |
| 2020-05-28 | 424B4 | 424B4 (final prospectus) | GENETIC TECHNOLOGIES LTD | 0001493152-20-009995 ↗ |
| 2024-01-04 | EFFECT | EFFECT (declared effective) | GENETIC TECHNOLOGIES LTD | 9999999995-24-000043 ↗ |
| 2024-05-20 | F-1 | F-1 (foreign registration) | GENETIC TECHNOLOGIES LTD | 0001493152-24-020503 ↗ |
| 2024-05-24 | EFFECT | EFFECT (declared effective) | GENETIC TECHNOLOGIES LTD | 9999999995-24-001651 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-05-12 | F-1/A | registration statement | 4,878,048 | - | Nasdaq GENE | 4 | primary document; shares headline, cover names 4 | document ↗ | ||
| 2020-05-28 | 424B4 | final prospectus | $2.00 | 500,000 | $1,000,000 | Nasdaq GENE | 2 | primary document; price line, shares headline, proceeds computed, cover names 2 | document ↗ |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), C3 first:
- MESOBLAST LTD C3
- BioNTech SE 2M
- Immatics N.V. 2M
- CHEMOKINE THERAPEUTICS CORP A1
- Fusion Pharmaceuticals Inc. A6
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. AZ
- Ablynx NV C9
- SANGAMO THERAPEUTICS, INC CA
- GENITOPE CORP CA
- ABGENIX INC CA
In other datasets, the same topic (Health) in C3:
- Form D issuer: Botanix Pharmaceuticals Ltd. (Form D private offerings)
Interests: Biological Products, (No Diagnostic Substances) · Health